CytomX Therapeutics Inc

NASDAQ:CTMX  
7.14
-0.08 (-1.11%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)460.31M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$16.59 Million
Adjusted EPS-$0.33
See more estimates
10-Day MA$7.20
50-Day MA$8.03
200-Day MA$7.57
See more pivots

CytomX Therapeutics Inc Stock, NASDAQ:CTMX

151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080-1913
United States of America
Phone: +1.605.515.3185
Number of Employees: 146

Description

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.